HTR7
ENSG00000148680
Target class
GPCR
Chromosome
10
Approved drugs
3
Clinical candidates (approved and in development)
5
- Approved drugs
- 3
- Clinical candidates (approved and in development)
- 5
- Chemical probe available
- Yes
- Other names
- 5-HT7
- Target name
- HTR7
- Gene name
- 5-hydroxytryptamine receptor 7
- Gene symbol
- HTR7
- Protein name
- 5-hydroxytryptamine receptor 7 (5-HT-7) (5-HT7) (5-HT-X) (Serotonin receptor 7)
- Gene biotype
- Protein coding
- Gene family
- 5-hydroxytryptamine receptors, G protein-coupled
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 8
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 13.83
- Tissue specificity (Gini)
- 0.647
- Tissue specificity (tau)
- 0.958
- KEGG gene identifiers
- hsa:3363
- Protein interaction confidence
- 0.892333
- Protein interaction partners
- 24
- R-HSA-390666
- R-HSA-418555
- End position
- 90858039
- Start position
- 90740823
- Chromosome
- 10
- Strand
- Reverse
- Cell membrane
- Multi-pass membrane protein .
- Nucleoplasm
- Plasma membrane
- Primary cilium
- PubMed 22448645
- PubMed 35714614
- Tissue specificity (tau)
- 0.958335
- Expression inequality (Gini)
- 0.64708
Expression in transcripts per million
- Testis
- 13.83
- Cells - Cultured fibroblasts
- 4.34
- Artery - Aorta
- 2.49
- Bladder
- 1.71
- Brain - Hypothalamus
- 1.7
Expression in transcripts per million
- Testis13.83
- Cells - Cultured fibroblasts4.34
- Artery - Aorta2.49
- Bladder1.71
- Brain - Hypothalamus1.7
- Artery - Coronary1.5
- Brain - Anterior cingulate cortex (BA24)1.29
- Vagina1.01
- Small Intestine - Terminal Ileum0.99
- Adipose - Subcutaneous0.89
- Brain - Frontal Cortex (BA9)0.83
- Stomach0.82
- Nerve - Tibial0.8
- Skin - Sun Exposed (Lower leg)0.73
- Esophagus - Mucosa0.71
- Artery - Tibial0.59
- Breast - Mammary Tissue0.57
- Brain - Cortex0.57
- Brain - Hippocampus0.48
- Colon - Transverse0.45
- Colon - Sigmoid0.45
- Lung0.45
- Prostate0.43
- Minor Salivary Gland0.43
- Cervix - Endocervix0.4
And 29 more, listed on the interactive page.
- GO:0007187
- GO:0007192
- GO:0007268
- GO:0007623
- GO:0008015
- GO:0005886
- GO:0005929
- GO:0032588
- GO:0004993
- GO:0005515
decreased inflammation
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased inflammation
- nervous system
- immune
PubMed 28216264increased/decreased memory
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased/decreased memory
- nervous system
- immune
PubMed 28216264decreased body temperature
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased body temperature
- nervous system
- immune
PubMed 28216264decreased anxiety
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased anxiety
- nervous system
- immune
PubMed 28216264decreased pain
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased pain
- nervous system
- immune
PubMed 28216264decreased/increased pain
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased/increased pain
- nervous system
- immune
PubMed 28216264decreased sleep
- Inhibition/Decrease/Downregulation: acute
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased sleep
- nervous system
- immune
PubMed 28216264increased memory
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased memory
- nervous system
- immune
PubMed 28216264
receptor binding
Studies
- biochemical: NVS_GPCR_h5HT7, is one of one assay component(s) measured or calculated from the NVS_GPCR_h5HT7 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.
Biological samples
- cell-free
Evidence source
Related records
Trials (1,449)
- "Brexpiprazole (Rexulti™) Safety and Efficacy Among Filipino Patients (RAISE) - A Post Marketing Surveillance Program"
- "Extended" (Alternate Day) Antipsychotic Dosing
- "Olanzapine for Prevention of Chemotherapy Induced Nausea and Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy (HEC)"
- [11C]Yohimbine PET Study of alpha2-AR
- 1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain
- 12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients
- 15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated
- 18F-DOPA PET to Elucidate the Antidepressant Mechanism of Lurasidone in Bipolar Disorder
- 24-Hour Time Course of Striatal Dopamine D2 Receptor Occupancy of Ziprasidone: A PET Study
- 28-30 Month Study Comparing Paliperidone Palmitate With Oral Risperidone for Treating Adults Diagnosed With Schizophrenia Within the Past 5 Years
- 3-Week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07008)
- 3-week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07009)
- 3-week Study to Evaluate Efficacy and Safety of Ziprasidone With Either Lithium or Divalproex in Acutely Manic Subjects
- 40 Week Extension Study Of Asenapine and Olanzapine For Bipolar Disorder (A7501007)(COMPLETED)(P05857)
- 5-HTR2A, DRD2,and COMT Genes Polymorphisms and Olanzapine Plasma Concentration in Treatment of Early-onset Schizophrenia
- 5HT3 Antagonism and Auditory Gating in Schizophrenia
- 6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptom Patients Who Completed the Protocol 25543 (25544)(P05777)
- 6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptoms Patients Who Completed the First 6- Month Trial (A7501014)(COMPLETED)(P05772)
- 9 Week Extension Study of Asenapine and Olanzapine in Treatment of Mania (P07007)(COMPLETED)
- A 10-Week, Open-Label, Flexible Dose Adaptive Study Evaluating the Efficacy of Vortioxetine in Subjects With Panic Disorder
Drugs (40)
- Amisulpride Serotonin (5-HT) receptor antagonist
- Brexpiprazole
- Capeserod
- Chlorpromazine
- Clozapine
- Cyamemazine
- Cyproheptadine
- Dexfenfluramine Serotonin (5-HT) receptor agonist
- Dexfenfluramine hydrochloride Serotonin (5-HT) receptor agonist
- Dihydroergotamine
- Fluperlapine
- Fluphenazine
- Haloperidol
- Iloperidone
- JNJ-18038683 Serotonin 7 (5-HT7) receptor antagonist
- JNJ-18038683 FREE BASE Serotonin 7 (5-HT7) receptor antagonist
- Ketanserin
- Lurasidone
- LY2590443 Serotonin 7 (5-HT7) receptor antagonist
- Mesulergine